ALG versus OKT3 for treatment of steroid-resistant rejection in renal transplantation: ten-year follow-up results of a randomized trial.
Stippel
D L
DL
Department of Surgery, University of Cologne, Köln, Germany. dirk.stippel@uni-koeln.de
Arns
W
W
Pollok
M
M
Beckurts
K T E
KT
Hesse
U J
UJ
Hölscher
A H
AH
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002423:Cause of Death; D004351:Drug Resistance; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology; D006085:Graft Survival / Q000502:physiology*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D016019:Survival Analysis; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D000961:Antilymphocyte Serum; D016853:Muromonab-CD3